HOPA 2017 Oncology Pharmacy Updates Course - On Demand
Originally presented July 28–29, 2017
- Learn about promising research and new treatment regiments.
- Get clinical updates on treatment of tumor types and new supportive care therapies.
- Find an overview of common clinical and technical issues in the hematology/oncology clinical setting.
Statement of Need/Activity Purpose:
This webinar will highlight significant research developments and treatment advances from the ASCO Annual Meeting. Selected topics will feature innovations in therapies for hematologic malignancies and solid tumors, and supportive care interventions for adults and children with cancer.
Sessions and Speakers
BC1: Updates in Gastrointestinal Malignancies
Speaker: Sal Bottiglieri, PharmD BCOP
BC2: Progress and Controversies in the Management of Gynecologic Malignancies
Speaker: Evelyn Handel, PharmD BCOP BCPS
BC3: Updates in the Management of Acute Myeloid Leukemia
Speaker: Larry Buie, PharmD BCOP FASHP
BC4: Updates in Advanced Thyroid Cancer
Speaker: Milena Wong, PharmD BCOP
BC5: Updates in Multiple Myeloma
Speaker: Kathryn Schultz, PharmD BCOP BCPS
BC6: Updates in Hematopoietic Cell Transplantation
Speaker: Sarah Schmidt, PharmD BCOP BCPS
BC7: What’s New in CNS Tumors?
Speaker: Shauna Choi, PharmD BCOP
BC8: Updates in Pediatric Malignancies
Speaker: Joshua Elder, PharmD BCOP BCPS
BC9: Parole Officers for Painkillers
Speaker: Doreen Pon, PharmD BCOP BCPS
BC10: Updates in Renal Cell Carcinoma
Speaker: Kinjal Parikh, PharmD BCOP
Primary Target Audience
Board certified hematology/oncology pharmacists
Advanced practice oncology pharmacists
Continuing Pharmacy Education Information
Statement of Need/Course Overview
HOPA organizes the oncology pharmacy updates course for board certified hematology/oncology pharmacy practitioners to educate attendees about emerging research and new treatment regimens, and provide clinical updates on treatment of tumor types and new supportive care therapies. The overall goal of educating oncology pharmacy practitioners about current developments is to improve the efficiency of healthcare delivery while maintaining or exceeding the quality of patient care. By informing hematology/oncology practitioners about the latest developments in clinical trials, therapeutic regimens, treatment guidelines, and emerging technologies, these individuals will be well positioned to participate in healthcare initiatives and clinical decision making that will have a direct and positive impact on cancer patient management.
Objectives of the 2017 Oncology Pharmacy Updates Course include educating attendees on updates in the management of cancers and supportive care. Ten select topics will be covered at least every 3 years and will cover new and ongoing therapeutic developments that have emerged within the last 3 years.
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certification oncology credit (BCOP). A BCOP statement of credit will be issued only upon completion of a post-activity evaluation form and post-test, with a passing grade of 75% achieved. Tests must be completed by December 31, 2017.
Disclosure of Conflicts of Interest: The Hematology/Oncology Pharmacy Association (HOPA) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by HOPA for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. HOPA is committed to providing its learners with high-quality CE activities and related materials that promote improvements of quality in healthcare and not a specific proprietary business interest of a commercial interest.
Reported Areas of Conflict: Planners and Managers Hematology/Oncology Pharmacy Association does not view the existence of relationships as an implication of bias or that the value of the material is decreased. The content of the activity was planned to be balanced, objective, and scientifically rigorous. Occasionally, authors may express opinions that represent their own viewpoint. Conclusions drawn by participants should be derived from objective analysis of scientific data. Unlabeled/unapproved uses of drugs. All faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs and devices.
Disclosure of Conflicts of Interest: HOPA assesses conflicts of interest with its faculty, planners, managers, and other individuals who are in a position to control the content of CPE activities. All potential conflicts of interest identified are thoroughly reviewed for fair balance, scientific objectivity of studies used in the activity, and patient care recommendations. HOPA is committed to providing its learners with high-quality CPE activities and related materials that promote improvements or quality in health care and not specific proprietary commercial interests.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the U.S. Food and Drug Administration. HOPA and its faculty, planners, managers, and commercial supporters do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activities are those of the faculty and do not necessarily represent the views of HOPA or any other organizational or commercial entities.
Resolution of Conflict of InterestIn accordance with the ACPE Standards for Commercial Support of CPE, the Hematology/Oncology Pharmacy Association has implemented mechanisms, prior to the planning and implementation of this CPE activity, to identify and mitigate conflicts of interest for all individuals in a position to control the content of this CPE activity.
The Hematology/Oncology Pharmacy Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Successful completion of this program will provide a statement for up to 10 contact hours of credit and will be available at the completion of the activity. Successful completion includes participating in the activity and completing self-assessment and program evaluation form online. A statement of participation will be available online immediately following successful completion of the activity.
Each module will include access to articles, learning objectives, pre & post-assessments, patient cases and/or case—based discussion and the BCOP web-based post test. Participants must achieve a 75% passing grade to obtain BCOP Recertification credit.Participants may earn up to 10 hours of credit.
Individual webinar pricing: $225 (member) / $325 (non-member)